Allianz Asset Management GmbH Has $1.37 Million Stake in Merus N.V. $MRUS

Allianz Asset Management GmbH lifted its position in shares of Merus N.V. (NASDAQ:MRUS) by 66.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,000 shares of the biotechnology company’s stock after buying an additional 10,400 shares during the period. Allianz Asset Management GmbH’s holdings in Merus were worth $1,368,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Voya Investment Management LLC boosted its position in shares of Merus by 26.3% during the first quarter. Voya Investment Management LLC now owns 78,280 shares of the biotechnology company’s stock worth $3,295,000 after buying an additional 16,280 shares during the period. Atle Fund Management AB raised its holdings in Merus by 69.7% during the second quarter. Atle Fund Management AB now owns 59,889 shares of the biotechnology company’s stock worth $3,150,000 after acquiring an additional 24,597 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Merus by 15.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,674 shares of the biotechnology company’s stock worth $141,000 after acquiring an additional 362 shares in the last quarter. US Bancorp DE raised its holdings in Merus by 324.1% during the first quarter. US Bancorp DE now owns 2,935 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 2,243 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Merus by 30.0% during the first quarter. PNC Financial Services Group Inc. now owns 5,800 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 1,340 shares in the last quarter. 96.14% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MRUS has been the topic of several analyst reports. Barclays reiterated an “equal weight” rating and set a $97.00 target price (down previously from $112.00) on shares of Merus in a report on Tuesday, September 30th. Guggenheim reiterated a “neutral” rating and set a $97.00 target price (down previously from $109.00) on shares of Merus in a report on Tuesday, September 30th. William Blair lowered Merus from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. Leerink Partners reiterated a “market perform” rating and set a $97.00 target price (up previously from $95.00) on shares of Merus in a report on Monday, October 6th. Finally, Citigroup lowered Merus from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $101.00 to $97.00 in a report on Monday, September 29th. Four research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $93.12.

Merus Stock Up 0.5%

MRUS stock opened at $94.88 on Friday. The company has a market cap of $7.18 billion, a PE ratio of -17.25 and a beta of 1.26. Merus N.V. has a 52 week low of $33.19 and a 52 week high of $95.06. The business has a 50-day simple moving average of $78.15 and a 200 day simple moving average of $61.53.

Merus (NASDAQ:MRUS) last released its earnings results on Tuesday, August 5th. The biotechnology company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($1.06). The business had revenue of $8.83 million for the quarter, compared to the consensus estimate of $9.77 million. Merus had a negative return on equity of 50.28% and a negative net margin of 685.64%. On average, analysts anticipate that Merus N.V. will post -3.85 EPS for the current fiscal year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.